Research overview
What is Follistatin 344?
Follistatin is a binding protein involved in regulating several TGF-beta-family signaling molecules. “FS344” identifies one gene-encoded isoform precursor in the published gene-transfer work. It is not a short synthetic research peptide, and the expression product of a viral vector differs from a separately manufactured protein formulation.
What has research examined?
A small phase 1/2a study in people with Becker muscular dystrophy used an adeno-associated viral vector carrying the FS344 sequence and assessed safety and exploratory muscle outcomes. The intervention was delivery of a gene, not a measured mass of protein solution. Follow-up publications discuss ambulation and the rationale for choosing this isoform, but their findings cannot establish efficacy or safety for an independently sourced Follistatin 344 vial.
The gene-transfer study and research protein are materially different products. Small exploratory outcomes cannot be turned into a generic muscle-growth claim, and no syringe conversion can bridge that gap. This page does not recommend an intervention, amount, or use.
Research references
- A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophyMolecular Therapy
- Follistatin Gene Therapy Improves Ambulation in Becker Muscular DystrophyCurrent Gene Therapy; follow-up discussion
Calculation boundary
The frequently cited FS344 human study used a viral vector to deliver a gene encoding a follistatin isoform, not reconstituted Follistatin 344 protein from a vial. A generic mass-volume syringe chart would incorrectly imply that the gene-transfer intervention and a supplier’s protein are equivalent.